RemeGen has raised $515 million on the Hong Kong alternate in one of many largest biotech IPOs ever produced.
The most important thus far in 2020, and one of many largest after Moderna’s $600 million-plus IPO a number of years again, the Yantai-based biotech in China will use its main money haul towards its wholesome pipeline of mid- to late-stage efforts.
This consists of telitacicept and disitamab vedotin, each slated for approval inside the subsequent three to eight months.
The previous remedy is geared toward B cell-mediated autoimmune illnesses, with an preliminary give attention to systemic lupus erythematosus, a situation that has seen its share of R&D setbacks, although a constant sequence of analysis lately has buoyed hopes of a renaissance within the space.
Disitamab vedotin, in the meantime, works as an in-demand antibody-drug conjugate concentrating on HER2 cancers, with a give attention to gastric, urothelial and HER2-low-expressing breast cancers.
Additional again within the pipeline, it additionally has a sequence of early-stage medicine engaged on fusion protein VEGFR/FGF in eye circumstances together with moist age-related macular degeneration and diabetic macular edema.